NASDAQ$GH
Guardant Health Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Guardant Health's revenue increased by 27% year-over-year, driven by growth in clinical and biopharma test volumes.
Guardant Health reported a 27% increase in revenue for the third quarter of 2021, reaching $94.8 million. The company saw significant growth in clinical and biopharma test volumes, despite the continued impact of COVID-19. However, the net loss also increased to $107.5 million, or $1.06 per share.
- Revenue reached $94.8 million, a 27% increase compared to the third quarter of 2020.
- Clinical tests increased by 35% year-over-year, with 22,806 tests reported.
- Biopharmaceutical tests increased by 58% year-over-year, with 4,839 tests reported.
- ORACLE study initiated to evaluate Guardant Reveal™ for predicting recurrence across eleven early-stage cancers.
Headline financials
Revenue & EPS history
Guardant Health · Revenue · Quarterly
$94.8M
Revenue by segment
Guardant Health · $79.3M total across 1 segment · Q3 2021
- Oncology Revenue$79.3M+31.3%100.0%
Forward guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020.
Tailwinds
- Full year 2021 revenue expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% expected over full year 2020.
- Expansion of product portfolio with focus on early-stage cancer detection.
- Continued progress in developing blood-based cancer screening tests.
- Focus on improving patient clinical outcomes and lowering healthcare costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+3.8%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+3.9%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+41.3%
Q4 2018
Best reaction
-30.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +6.6% | +36.1% | |
| Q4 2025 | -3.0% | -10.4% | -19.9% | |
| Q3 2025 | +28.5% | +35.8% | +50.0% | |
| Q1 2025 | +3.5% | -11.2% | -14.0% | |
| Q4 2024 | -9.6% | -8.9% | -2.7% | |
| Q3 2024 | +21.6% | +24.8% | +56.8% | |
| Q2 2024 | -5.9% | -5.3% | -26.2% | |
| Q1 2024 | +20.0% | +32.7% | +53.8% | |
| Q4 2023 | -14.3% | -13.8% | -23.9% | |
| Q3 2023 | -8.5% | -24.7% | -10.2% | |
| Q2 2023 | +4.6% | +1.9% | -3.1% | |
| Q1 2023 | +17.2% | +12.1% | +38.5% | |
| Q4 2022 | +4.4% | +11.7% | -12.6% | |
| Q3 2022 | +3.3% | -3.1% | +17.5% | |
| Q2 2022 | +1.6% | -6.0% | +2.0% | |
| Q1 2022 | -30.0% | -44.3% | -32.3% | |
| Q4 2021 | +6.0% | +7.0% | -4.3% | |
| Q3 2021 | -3.8% | -5.8% | -20.8% | |
| Q2 2021 | +0.2% | -7.7% | +15.7% | |
| Q1 2021 | -3.1% | -14.0% | -15.8% | |
| Q4 2020 | -6.7% | -5.0% | -15.3% | |
| Q3 2020 | -0.4% | -1.1% | +9.0% | |
| Q2 2020 | +0.6% | -4.0% | +6.8% | |
| Q1 2020 | +9.0% | +19.6% | +2.9% | |
| Q4 2019 | -14.7% | -2.1% | -25.9% | |
| Q3 2019 | +11.2% | +13.8% | +14.4% | |
| Q2 2019 | +25.8% | +18.2% | -5.2% | |
| Q1 2019 | +17.4% | +12.0% | +40.3% | |
| Q4 2018 | +41.3% | +46.6% | +7.9% | |
| Q3 2018 | -6.7% | +3.1% | -2.7% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro